{"hands_on_practices": [{"introduction": "A foundational challenge in AAV vector engineering is its finite packaging capacity. This exercise provides a practical walkthrough of the \"genetic accounting\" required in the initial design phase of a gene therapy vector. By systematically subtracting the lengths of essential non-coding elements—such as promoters, enhancers, and polyadenylation signals—from the AAV genome's total limit, you will determine the maximum allowable size for a therapeutic transgene, a critical first step in assessing the feasibility of any AAV-based project [@problem_id:5016982].", "problem": "A translational medicine team is designing a single-stranded Adeno-Associated Virus (AAV) gene therapy vector for clinical use. The capsid imposes an upper bound on the length of the packaged genome. In AAV, the genome that is packaged includes both essential Inverted Terminal Repeats (ITRs), and the remaining portion available for the expression cassette must accommodate all regulatory elements needed for transcription, RNA processing, and post-transcriptional enhancement.\n\nAssume the following scenario:\n- The total AAV packaging limit (including both ITRs) is $4.7$ kilobases (kb), and use $1$ kb $=$ $1000$ base pairs (bp).\n- Each ITR is $145$ bp.\n- The expression cassette will include the following regulatory elements, each considered necessary for robust expression in human somatic cells:\n  - A cytomegalovirus promoter (CMV promoter) of $600$ bp.\n  - A generic enhancer module of $300$ bp.\n  - A synthetic intron (to enhance transcriptional output and mRNA maturation) of $500$ bp.\n  - A woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) of $600$ bp.\n  - A polyadenylation (polyA) signal of $250$ bp.\n\nStarting from foundational definitions about vector genome composition and packaging constraints, derive an expression for the maximum open reading frame (ORF) length $L_{\\mathrm{ORF}}$ available for the coding sequence as a function of the total packaging limit, the ITR lengths, and the regulatory element lengths. Then, compute $L_{\\mathrm{ORF}}$ for the values specified above. Round your final numerical result to four significant figures and express it in base pairs (bp).", "solution": "The problem statement has been validated and is deemed valid. It is scientifically grounded in the principles of molecular biology and gene therapy vector design, is well-posed with sufficient and consistent data, and is expressed in objective language. There are no identifiable flaws.\n\nThe problem requires the derivation of an expression for the maximum length of an open reading frame (ORF), denoted as $L_{\\mathrm{ORF}}$, that can be packaged into an Adeno-Associated Virus (AAV) vector, and then to compute this length using the provided values.\n\nThe fundamental principle governing AAV vector design is that the total length of the single-stranded DNA genome to be packaged must not exceed the capsid's packaging capacity. We are given this total packaging limit, $L_{\\mathrm{total}}$. To maximize the length of the variable component, $L_{\\mathrm{ORF}}$, we must assume that the total length of the constructed genome is exactly equal to this limit.\n$$L_{\\mathrm{genome}} = L_{\\mathrm{total}}$$\nThe genome to be packaged, $L_{\\mathrm{genome}}$, is composed of several functional parts ligated together in a specific order. These parts are the two Inverted Terminal Repeats (ITRs) that flank the expression cassette. The expression cassette itself contains the necessary regulatory elements and the therapeutic ORF.\n\nThe total length of the genome is the sum of the lengths of its components:\n$$L_{\\mathrm{genome}} = (\\text{length of two ITRs}) + (\\text{length of the expression cassette})$$\nThe AAV genome is flanked by two ITRs, each of length $L_{\\mathrm{ITR}}$. Therefore, the total length contributed by the ITRs is $2 \\cdot L_{\\mathrm{ITR}}$.\n\nThe expression cassette contains all other elements. The total length of the regulatory elements can be defined as $L_{\\mathrm{reg}}$, which is the sum of the lengths of the promoter ($L_{\\mathrm{promoter}}$), enhancer ($L_{\\mathrm{enhancer}}$), intron ($L_{\\mathrm{intron}}$), WPRE ($L_{\\mathrm{WPRE}}$), and polyadenylation signal ($L_{\\mathrm{polyA}}$).\n$$L_{\\mathrm{reg}} = L_{\\mathrm{promoter}} + L_{\\mathrm{enhancer}} + L_{\\mathrm{intron}} + L_{\\mathrm{WPRE}} + L_{\\mathrm{polyA}}$$\nThe expression cassette's total length is the sum of the regulatory elements' length and the ORF's length:\n$$L_{\\mathrm{cassette}} = L_{\\mathrm{reg}} + L_{\\mathrm{ORF}}$$\nCombining these components, the total genome length can be expressed as:\n$$L_{\\mathrm{total}} = 2 \\cdot L_{\\mathrm{ITR}} + L_{\\mathrm{reg}} + L_{\\mathrm{ORF}}$$\nSubstituting the expanded form of $L_{\\mathrm{reg}}$ yields the full relationship:\n$$L_{\\mathrm{total}} = 2 \\cdot L_{\\mathrm{ITR}} + L_{\\mathrm{promoter}} + L_{\\mathrm{enhancer}} + L_{\\mathrm{intron}} + L_{\\mathrm{WPRE}} + L_{\\mathrm{polyA}} + L_{\\mathrm{ORF}}$$\nTo find the maximum available length for the ORF, we rearrange this equation to solve for $L_{\\mathrm{ORF}}$:\n$$L_{\\mathrm{ORF}} = L_{\\mathrm{total}} - 2 \\cdot L_{\\mathrm{ITR}} - (L_{\\mathrm{promoter}} + L_{\\mathrm{enhancer}} + L_{\\mathrm{intron}} + L_{\\mathrm{WPRE}} + L_{\\mathrm{polyA}})$$\nThis is the general expression for the maximum ORF length.\n\nNow, we will compute the numerical value for $L_{\\mathrm{ORF}}$ using the given data. First, all lengths must be in the same unit, which will be base pairs (bp).\nThe total packaging limit is given as $L_{\\mathrm{total}} = 4.7$ kb. Using the conversion $1$ kb = $1000$ bp:\n$$L_{\\mathrm{total}} = 4.7 \\text{ kb} \\times \\frac{1000 \\text{ bp}}{1 \\text{ kb}} = 4700 \\text{ bp}$$\nThe lengths of the other components are given in bp:\n- Length of one ITR: $L_{\\mathrm{ITR}} = 145$ bp.\n- Promoter length: $L_{\\mathrm{promoter}} = 600$ bp.\n- Enhancer length: $L_{\\mathrm{enhancer}} = 300$ bp.\n- Intron length: $L_{\\mathrm{intron}} = 500$ bp.\n- WPRE length: $L_{\\mathrm{WPRE}} = 600$ bp.\n- PolyA signal length: $L_{\\mathrm{polyA}} = 250$ bp.\n\nFirst, calculate the total length of the two ITRs:\n$$2 \\cdot L_{\\mathrm{ITR}} = 2 \\cdot 145 \\text{ bp} = 290 \\text{ bp}$$\nNext, calculate the sum of the lengths of all regulatory elements, $L_{\\mathrm{reg}}$:\n$$L_{\\mathrm{reg}} = 600 \\text{ bp} + 300 \\text{ bp} + 500 \\text{ bp} + 600 \\text{ bp} + 250 \\text{ bp} = 2250 \\text{ bp}$$\nNow, substitute these values into the expression for $L_{\\mathrm{ORF}}$:\n$$L_{\\mathrm{ORF}} = L_{\\mathrm{total}} - 2 \\cdot L_{\\mathrm{ITR}} - L_{\\mathrm{reg}}$$\n$$L_{\\mathrm{ORF}} = 4700 \\text{ bp} - 290 \\text{ bp} - 2250 \\text{ bp}$$\n$$L_{\\mathrm{ORF}} = 4700 \\text{ bp} - 2540 \\text{ bp}$$\n$$L_{\\mathrm{ORF}} = 2160 \\text{ bp}$$\nThe calculated value is $2160$ bp. The problem requires the result to be rounded to four significant figures. The number $2160$ is an exact integer. To express it with four significant figures unambiguously, it is best written in scientific notation as $2.160 \\times 10^3$.", "answer": "$$\\boxed{2.160 \\times 10^3}$$", "id": "5016982"}, {"introduction": "Moving from vector design to biological application, it is crucial to understand that not every vector particle results in successful gene expression. This practice models the multi-stage journey of an AAV vector from the extracellular space to the host cell nucleus, accounting for the probabilistic nature of each biological barrier. By applying a Poisson statistical model, you will learn to predict the fraction of cells that will be successfully transduced at a given dose, a key skill for designing and interpreting both *in vitro* experiments and preclinical studies [@problem_id:5017047].", "problem": "A translational medicine team is optimizing an in vitro dosing strategy for Adeno-Associated Virus (AAV) gene delivery to primary human hepatocytes. The vector preparation has a measured physical titer of $4.0 \\times 10^{11}$ vector genomes per milliliter (vg/mL). A single dose consisting of $50\\,\\mu\\text{L}$ of this preparation is added to a culture containing $3.0 \\times 10^{7}$ hepatocytes. Based on independent and well-characterized steps in the AAV life cycle, the following efficiencies apply uniformly to all particles in this exposure: receptor-binding efficiency $0.05$, internalization efficiency $0.40$, endosomal escape efficiency $0.25$, nuclear entry and second-strand synthesis success probability $0.30$, fraction of full capsids (i.e., capsids containing complete vector genomes) $0.60$, and survival fraction in the presence of neutralizing antibodies $0.60$. Assume the following foundational principles:\n- The multiplicity of infection (MOI) is defined as the average number of productive genome delivery events per cell.\n- Independent Bernoulli filtering steps multiplicatively reduce the expected number of productive delivery events.\n- If productive genome delivery events to each cell are independent and rare, the number of such events per cell is well modeled by a Poisson distribution.\n\nUsing these bases, derive the mean number of productive genome delivery events per cell and from it compute the predicted fraction of transduced cells after this single exposure, defined as the fraction of cells that receive at least one productive genome delivery event. Express your final result as a dimensionless decimal and round your answer to four significant figures.", "solution": "The problem statement must first be validated for scientific soundness, completeness, and objectivity.\n\n### Step 1: Extract Givens\nThe following data and principles are explicitly provided in the problem statement:\n-   Vector preparation physical titer, $T_{phys}$: $4.0 \\times 10^{11}$ vector genomes per milliliter (vg/mL).\n-   Dose volume, $V_{dose}$: $50\\,\\mu\\text{L}$.\n-   Number of hepatocytes, $N_{cell}$: $3.0 \\times 10^{7}$.\n-   Receptor-binding efficiency, $\\eta_{bind}$: $0.05$.\n-   Internalization efficiency, $\\eta_{int}$: $0.40$.\n-   Endosomal escape efficiency, $\\eta_{esc}$: $0.25$.\n-   Nuclear entry and second-strand synthesis success probability, $\\eta_{nuc}$: $0.30$.\n-   Fraction of full capsids, $\\eta_{full}$: $0.60$.\n-   Survival fraction in the presence of neutralizing antibodies, $\\eta_{surv}$: $0.60$.\n-   Definition: Multiplicity of infection (MOI) is the average number of productive genome delivery events per cell.\n-   Principle 1: Independent Bernoulli filtering steps multiplicatively reduce the expected number of productive delivery events.\n-   Principle 2: The number of productive genome delivery events per cell is well modeled by a Poisson distribution.\n-   Objective: Derive the mean number of productive genome delivery events per cell and compute the predicted fraction of transduced cells, rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed against the required criteria.\n-   **Scientifically Grounded**: The problem is grounded in the established principles of virology and gene therapy, specifically concerning the delivery of AAV vectors. The concept of a physical titer (total particles) versus a functional or infectious titer is fundamental. The sequence of cellular events—binding, internalization, endosomal escape, and nuclear entry—is a standard and well-characterized pathway. The use of a Poisson distribution to model the number of independent, rare events (like successful viral transduction) per entity (a cell) is a standard and appropriate statistical method in biology. All efficiency values, while specific to this hypothetical scenario, are within a plausible range for *in vitro* experiments.\n-   **Well-Posed**: The problem provides all necessary quantitative data (titer, volume, cell count, efficiencies) and a clear statistical framework (Poisson distribution) to arrive at a unique numerical solution. The objective is clearly stated.\n-   **Objective**: The language is technical, precise, and devoid of subjective or ambiguous terminology.\n\n### Step 3: Verdict and Action\nThe problem is scientifically sound, self-contained, and well-posed. No flaws are identified. Therefore, the problem is deemed **valid**, and a full solution can be derived.\n\n### Solution Derivation\nThe solution proceeds by first calculating the total number of vector genomes applied to the cell culture. Then, the overall probability of a single vector genome resulting in a productive delivery event is determined by multiplying the efficiencies of all intermediate steps. This allows for the calculation of the mean number of productive events per cell, $\\lambda$, which corresponds to the problem's definition of MOI. Finally, the Poisson distribution model is used to compute the fraction of cells that receive at least one productive event.\n\nFirst, we calculate the total number of vector genomes (vg) added to the culture. The dose volume must be converted from microliters ($\\mu\\text{L}$) to milliliters (mL) to match the units of the titer.\n$$V_{dose} = 50\\,\\mu\\text{L} = 50 \\times 10^{-3}\\,\\text{mL} = 5.0 \\times 10^{-2}\\,\\text{mL}$$\nThe total number of vector genomes, $N_{vg}$, is the product of the physical titer, $T_{phys}$, and the dose volume, $V_{dose}$.\n$$N_{vg} = T_{phys} \\times V_{dose} = (4.0 \\times 10^{11}\\,\\text{vg/mL}) \\times (5.0 \\times 10^{-2}\\,\\text{mL}) = 20 \\times 10^{9}\\,\\text{vg} = 2.0 \\times 10^{10}\\,\\text{vg}$$\n\nNext, we calculate the overall efficiency, $\\eta_{total}$, which is the probability that a randomly selected particle from the preparation will result in a productive genome delivery event. According to the problem's principles, this is the product of all individual efficiency factors.\n$$\\eta_{total} = \\eta_{full} \\times \\eta_{surv} \\times \\eta_{bind} \\times \\eta_{int} \\times \\eta_{esc} \\times \\eta_{nuc}$$\nSubstituting the given values:\n$$\\eta_{total} = (0.60) \\times (0.60) \\times (0.05) \\times (0.40) \\times (0.25) \\times (0.30)$$\n$$\\eta_{total} = 0.36 \\times 0.05 \\times 0.40 \\times 0.25 \\times 0.30$$\n$$\\eta_{total} = 0.018 \\times 0.40 \\times 0.25 \\times 0.30$$\n$$\\eta_{total} = 0.0072 \\times 0.25 \\times 0.30$$\n$$\\eta_{total} = 0.0018 \\times 0.30$$\n$$\\eta_{total} = 0.00054 = 5.4 \\times 10^{-4}$$\n\nThe mean number of productive genome delivery events per cell, which we denote as $\\lambda$ (the parameter of the Poisson distribution), is the total number of expected productive events in the culture divided by the total number of cells. The total number of productive events is the initial number of vector genomes, $N_{vg}$, multiplied by the overall efficiency, $\\eta_{total}$.\n$$\\lambda = \\frac{N_{vg} \\times \\eta_{total}}{N_{cell}}$$\nSubstituting the calculated and given values:\n$$\\lambda = \\frac{(2.0 \\times 10^{10}) \\times (5.4 \\times 10^{-4})}{3.0 \\times 10^{7}}$$\n$$\\lambda = \\frac{10.8 \\times 10^{6}}{3.0 \\times 10^{7}} = \\frac{1.08 \\times 10^{7}}{3.0 \\times 10^{7}} = 0.36$$\nThus, the mean number of productive genome delivery events per cell is $0.36$. This is the MOI as defined in the problem.\n\nThe problem requires the fraction of transduced cells, defined as the fraction of cells that receive at least one productive genome delivery event. If the number of events per cell, $k$, follows a Poisson distribution with mean $\\lambda$, the probability of a cell receiving exactly $k$ events is given by:\n$$P(k; \\lambda) = \\frac{\\lambda^k \\exp(-\\lambda)}{k!}$$\nThe fraction of cells that are *not* transduced is the probability of a cell receiving zero events, $P(k=0)$.\n$$P(k=0; \\lambda=0.36) = \\frac{(0.36)^0 \\exp(-0.36)}{0!} = \\exp(-0.36)$$\nThe fraction of transduced cells is the complement, $P(k \\ge 1)$.\n$$P(k \\ge 1) = 1 - P(k=0) = 1 - \\exp(-0.36)$$\nNow, we compute the numerical value.\n$$P(k \\ge 1) = 1 - 0.6976763...$$\n$$P(k \\ge 1) = 0.3023236...$$\nThe problem requires the final answer to be rounded to four significant figures.\n$$P(k \\ge 1) \\approx 0.3023$$\nThis is the predicted fraction of transduced cells after the single exposure.", "answer": "$$ \\boxed{0.3023} $$", "id": "5017047"}, {"introduction": "The ultimate goal of translational medicine is to connect a therapeutic intervention to a clinical outcome. This final practice situates AAV gene therapy within a clinical context, using a real-world example to link the administered vector dose to a target physiological effect. By integrating principles of pharmacokinetics and cell biology, you will calculate the fraction of target cells (hepatocytes) that must be transduced to achieve a stable, therapeutic level of a secreted protein, thereby bridging the gap from molecular dosing to patient-level efficacy [@problem_id:5016979].", "problem": "A patient with severe hemophilia A is treated with valoctocogene roxaparvovec (Roctavian), an Adeno-Associated Virus (AAV) serotype 5 vector encoding B-domain deleted Factor VIII (FVIII). The infusion contains a vector genome concentration of $c_{\\mathrm{vg}} = 2.4 \\times 10^{13}\\ \\mathrm{vg/mL}$ and a total volume of $V_{\\mathrm{inf}} = 250\\ \\mathrm{mL}$. The patient’s body weight is $W = 75\\ \\mathrm{kg}$. \n\nAssume the following translational pharmacology model for circulating FVIII activity after successful hepatocyte transduction:\n- Plasma volume scales with body weight as $V_{\\mathrm{p}} = 45\\ \\mathrm{mL/kg} \\times W$.\n- FVIII exhibits first-order elimination with half-life $t_{1/2} = 12\\ \\mathrm{h}$, so the elimination rate constant is $k = \\ln(2)/t_{1/2}$.\n- A therapeutic target is $C_{\\mathrm{target}} = 40\\ \\mathrm{IU/dL}$ of FVIII activity in plasma, where $1\\ \\mathrm{dL} = 100\\ \\mathrm{mL}$.\n- At steady state, the production rate of active FVIII equals the elimination rate from plasma, and activity is conserved under first-order kinetics.\n- Each transduced hepatocyte secretes active FVIII at a mean rate of $r_{\\mathrm{cell}} = 1.0 \\times 10^{-11}\\ \\mathrm{IU/s}$, and the total hepatocyte count is $H = 1.5 \\times 10^{11}$ cells.\n\nUsing these assumptions and starting from the definitions of first-order elimination kinetics and mass balance, compute:\n1) The total administered dose per kilogram in vector genomes per kilogram, $D_{\\mathrm{vg/kg}}$.\n2) The fraction of hepatocytes that must be transduced, $f$, to sustain $C_{\\mathrm{target}}$ at steady state.\n\nExpress $D_{\\mathrm{vg/kg}}$ in vector genomes per kilogram (vg/kg) and $f$ as a unitless decimal fraction. Round both quantities to three significant figures.", "solution": "The problem statement has been validated and is deemed scientifically grounded, well-posed, and internally consistent. It provides a quantitative framework based on established principles of pharmacokinetics and cell biology to assess a gene therapy scenario. All necessary parameters and definitions are provided to compute the required quantities.\n\nThe solution is divided into two parts, corresponding to the two quantities requested.\n\n**Part 1: Calculation of the total administered dose per kilogram ($D_{\\mathrm{vg/kg}}$)**\n\nThe total administered dose in vector genomes per kilogram ($D_{\\mathrm{vg/kg}}$) is the total number of administered vector genomes ($N_{\\mathrm{vg}}$) divided by the patient's body weight ($W$).\n\nFirst, we calculate the total number of vector genomes, $N_{\\mathrm{vg}}$. This is the product of the vector genome concentration, $c_{\\mathrm{vg}}$, and the total infusion volume, $V_{\\mathrm{inf}}$.\nThe given values are:\n- Vector genome concentration, $c_{\\mathrm{vg}} = 2.4 \\times 10^{13}\\ \\mathrm{vg/mL}$\n- Infusion volume, $V_{\\mathrm{inf}} = 250\\ \\mathrm{mL}$\n\nThe total number of vector genomes is:\n$$N_{\\mathrm{vg}} = c_{\\mathrm{vg}} \\times V_{\\mathrm{inf}}$$\n$$N_{\\mathrm{vg}} = (2.4 \\times 10^{13}\\ \\mathrm{vg/mL}) \\times (250\\ \\mathrm{mL}) = 6.0 \\times 10^{15}\\ \\mathrm{vg}$$\n\nNext, we calculate the dose per kilogram of body weight, $D_{\\mathrm{vg/kg}}$, using the patient's weight, $W = 75\\ \\mathrm{kg}$.\n$$D_{\\mathrm{vg/kg}} = \\frac{N_{\\mathrm{vg}}}{W}$$\n$$D_{\\mathrm{vg/kg}} = \\frac{6.0 \\times 10^{15}\\ \\mathrm{vg}}{75\\ \\mathrm{kg}} = 8.0 \\times 10^{13}\\ \\mathrm{vg/kg}$$\nRounding to three significant figures as requested, the dose is $8.00 \\times 10^{13}\\ \\mathrm{vg/kg}$.\n\n**Part 2: Calculation of the fraction of transduced hepatocytes ($f$)**\n\nThe problem states that at steady state, the rate of Factor VIII (FVIII) production equals its rate of elimination. We must formulate expressions for both rates.\n\nThe rate of elimination, $R_{\\mathrm{elim}}$, is governed by first-order kinetics. It is the product of the first-order elimination rate constant, $k$, and the total amount of FVIII in the plasma, $A_{\\mathrm{FVIII}}$.\n$$R_{\\mathrm{elim}} = k \\times A_{\\mathrm{FVIII}}$$\n\nThe total amount of FVIII in the plasma, $A_{\\mathrm{FVIII}}$, is the product of the target steady-state concentration, $C_{\\mathrm{target}}$, and the plasma volume, $V_{\\mathrm{p}}$.\n$$A_{\\mathrm{FVIII}} = C_{\\mathrm{target}} \\times V_{\\mathrm{p}}$$\nWe are given:\n- Target concentration, $C_{\\mathrm{target}} = 40\\ \\mathrm{IU/dL}$. We must convert this to IU/mL using $1\\ \\mathrm{dL} = 100\\ \\mathrm{mL}$.\n$$C_{\\mathrm{target}} = 40\\ \\frac{\\mathrm{IU}}{\\mathrm{dL}} \\times \\frac{1\\ \\mathrm{dL}}{100\\ \\mathrm{mL}} = 0.4\\ \\mathrm{IU/mL}$$\n- Plasma volume, $V_{\\mathrm{p}}$, scales with body weight $W = 75\\ \\mathrm{kg}$ as $V_{\\mathrm{p}} = 45\\ \\mathrm{mL/kg} \\times W$.\n$$V_{\\mathrm{p}} = (45\\ \\mathrm{mL/kg}) \\times (75\\ \\mathrm{kg}) = 3375\\ \\mathrm{mL}$$\n\nSo, the total amount of FVIII is:\n$$A_{\\mathrm{FVIII}} = (0.4\\ \\mathrm{IU/mL}) \\times (3375\\ \\mathrm{mL}) = 1350\\ \\mathrm{IU}$$\n\nThe elimination rate constant, $k$, is related to the half-life, $t_{1/2}$, by $k = \\ln(2)/t_{1/2}$. We are given $t_{1/2} = 12\\ \\mathrm{h}$. To maintain unit consistency with the production rate (given in IU/s), we convert hours to seconds:\n$$t_{1/2} = 12\\ \\mathrm{h} \\times \\frac{3600\\ \\mathrm{s}}{1\\ \\mathrm{h}} = 43200\\ \\mathrm{s}$$\nThus, the rate constant is:\n$$k = \\frac{\\ln(2)}{43200\\ \\mathrm{s}}$$\n\nThe rate of elimination is therefore:\n$$R_{\\mathrm{elim}} = k \\times A_{\\mathrm{FVIII}} = \\frac{\\ln(2)}{43200\\ \\mathrm{s}} \\times 1350\\ \\mathrm{IU}$$\n\nThe rate of production, $R_{\\mathrm{prod}}$, is the total number of transduced hepatocytes, $N_{\\mathrm{transduced}}$, multiplied by the secretion rate per cell, $r_{\\mathrm{cell}}$. The number of transduced hepatocytes is the product of the fraction to be transduced, $f$, and the total number of hepatocytes, $H$.\n$$R_{\\mathrm{prod}} = N_{\\mathrm{transduced}} \\times r_{\\mathrm{cell}} = (f \\times H) \\times r_{\\mathrm{cell}}$$\nWe are given:\n- Total hepatocyte count, $H = 1.5 \\times 10^{11}$\n- Secretion rate per cell, $r_{\\mathrm{cell}} = 1.0 \\times 10^{-11}\\ \\mathrm{IU/s}$\n\nSo, the production rate is:\n$$R_{\\mathrm{prod}} = f \\times (1.5 \\times 10^{11}) \\times (1.0 \\times 10^{-11}\\ \\mathrm{IU/s}) = f \\times 1.5\\ \\mathrm{IU/s}$$\n\nAt steady state, $R_{\\mathrm{prod}} = R_{\\mathrm{elim}}$:\n$$f \\times 1.5\\ \\mathrm{IU/s} = \\frac{\\ln(2)}{43200\\ \\mathrm{s}} \\times 1350\\ \\mathrm{IU}$$\n\nWe can now solve for the fraction $f$:\n$$f = \\frac{1350 \\times \\ln(2)}{1.5 \\times 43200} = \\frac{1350 \\times \\ln(2)}{64800} = \\frac{\\ln(2)}{48}$$\nUsing the value $\\ln(2) \\approx 0.693147$:\n$$f \\approx \\frac{0.693147}{48} \\approx 0.01444056$$\nRounding to three significant figures, the fraction of hepatocytes that must be transduced is $f = 0.0144$.\n\nIn summary:\n1) $D_{\\mathrm{vg/kg}} = 8.00 \\times 10^{13}\\ \\mathrm{vg/kg}$\n2) $f = 0.0144$", "answer": "$$\\boxed{\\begin{pmatrix} 8.00 \\times 10^{13} & 0.0144 \\end{pmatrix}}$$", "id": "5016979"}]}